Ascendis Pharma slides 5.6% as investors digest recent run-up; no single headline catalyst apparent

Ascendis Pharma A/S (ASND) is down 5.6% today. Here is some analysis on what might have caused this price movement.

Analysis: No single, company-specific headline clearly explains today’s drop, so the move may reflect profit-taking after recent strength and normal volatility in biotech. This could also be tied to investors re-centering expectations following the company’s recent quarterly update and financing-related cleanup actions.

Details:

Ascendis’ most recent quarterly update (released May 7, 2026) highlighted strong product revenue led by YORVIPATH, but also flagged temporary impacts such as additional patients supported with free drug in the U.S. and a one-time Europe Direct effect tied to expanded access.

The company also disclosed it redeemed all outstanding $575 million of its 2.25% convertible senior notes due 2028 in early May, an event that can influence positioning and hedging activity around the stock.

A recent SEC Form 4 showed a director purchase of ordinary shares in late May, which suggests at least one insider viewed the pullback levels as attractive, even as the stock remains volatile.

This could be amplified by broader risk-off trading in high-multiple biotech names, where moves of 5%+ can occur without new fundamentals.

Sources:

Ascendis Pharma Investor Relations, U.S. SEC, Nasdaq

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$ASND Insider Trading Activity

$ASND insiders have traded $ASND stock on the open market 2 times in the past 6 months. Of those trades, 2 have been purchases and 0 have been sales.

Here’s a breakdown of recent trading of $ASND stock by insiders over the last 6 months:

JEAN JACQUES BIENAIME has made 2 purchases buying 400 shares for an estimated $95,120 and 0 sales.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

EARLY ACCESS

Receive ASND Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$ASND Hedge Fund Activity

We have seen 145 institutional investors add shares of $ASND stock to their portfolio, and 194 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

T. ROWE PRICE INVESTMENT MANAGEMENT, INC. removed 1,586,394 shares (-59.5%) from their portfolio in Q4 2025, for an estimated $338,282,656
PRICE T ROWE ASSOCIATES INC /MD/ removed 1,570,260 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $359,165,569
CAPITAL INTERNATIONAL INVESTORS removed 1,105,100 shares (-36.1%) from their portfolio in Q1 2026, for an estimated $252,769,523
CAPITAL WORLD INVESTORS added 900,517 shares (+inf%) to their portfolio in Q1 2026, for an estimated $205,975,253
CITADEL ADVISORS LLC removed 519,516 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $118,828,894
SUSQUEHANNA INTERNATIONAL GROUP, LLP removed 442,889 shares (-94.0%) from their portfolio in Q1 2026, for an estimated $101,302,000
WESTFIELD CAPITAL MANAGEMENT CO LP removed 372,256 shares (-7.2%) from their portfolio in Q1 2026, for an estimated $85,146,114

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$ASND Analyst Ratings

Wall Street analysts have issued reports on $ASND in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

B of A Securities issued a "Buy" rating on 01/30/2026
Stifel issued a "Buy" rating on 12/11/2025

To track analyst ratings and price targets for $ASND, check out Quiver Quantitative's $ASND forecast page.

$ASND Price Targets

Multiple analysts have issued price targets for $ASND recently. We have seen 11 analysts offer price targets for $ASND in the last 6 months, with a median target of $292.0.

Here are some recent targets:

Eric Joseph from Citigroup set a target price of $355.0 on 05/19/2026
Josh Schimmer from Evercore ISI Group set a target price of $329.0 on 05/15/2026
Eliana Merle from Barclays set a target price of $345.0 on 05/11/2026
Derek Archila from Wells Fargo set a target price of $326.0 on 05/08/2026
Tazeen Ahmad from B of A Securities set a target price of $292.0 on 04/16/2026
Yun Zhong from Wedbush set a target price of $273.0 on 04/09/2026
Kelly Shi from Jefferies set a target price of $290.0 on 03/16/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.